Trial · NCT06848075
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Freedom | 2 hours post-dose | Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) |
| Secondary | Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia) | 2 hours post-dose | Assessed using the number of evaluable participants that reported the absence of their MBS |
| Secondary | Pain Relief | 2 hours post-dose | Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1). |
| Secondary | Freedom From Photophobia | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline. |
| Secondary | Freedom From Phonophobia | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline. |
| Secondary | Freedom From Nausea | 2 hours post-dose | Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline. |
| Secondary | The Probability of Requiring Rescue Medication | 24 hours post-dose | Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy |
| Secondary | Sustained Pain Freedom | From 2 to 24 hours | Assessed using the number of participants that did not experience any headache pain through the time period of interest |
| Secondary | Sustained Pain Relief | From 2 to 24 hours | Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
| Secondary | Sustained Pain Freedom | From 2 to 48 hours | Assessed using the number of participants that did not experience any headache pain through the time period of interest. |
| Secondary | Sustained Pain Relief | From 2 to 48 hours | Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
| Secondary | Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs) | up to 7 days after administration of study therapy | |
| Secondary | Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs) | Up to 7 days after administration of study therapy | Serious adverse events were assessed in the Safety Analysis Set. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06848075/registered